shutterstock-163310765-3

Andy P / Shutterstock.com

30 May 2014Europe

Imanova: investing in know-how

Given the spiralling costs and ever-present risks associated with developing a new drug, pharmaceutical companies are always looking for ways to shorten the pathway from lab bench to clinic.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

GSK triumphs in EPO appeal, revoking Pfizer patent

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

CRISPR patents revoked following Nobel Prize winners’ withdrawal

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?